Differences in Graft-versus-Host Disease Characteristics between Haploidentical Transplantation Using Post-Transplantation Cyclophosphamide and Matched Unrelated Donor Transplantation Using Calcineurin Inhibitors
Biology of Blood and Marrow Transplantation · 2020-11 · 26 (11) · 2082-2088
DOI: 10.1016/j.bbmt.2020.07.035 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biology of Blood and Marrow Transplantation, 2020-11. Verfasst von Melhem M Solh und 6 weiteren Autor:innen. Beteiligte Einrichtung: Blood and Marrow Transplant Program at Northside Hospital, Atlanta, Georgia. Electronic address: msolh@bmtga.com. Hauptthemen laut MEDLINE: Graft vs Host Disease, Hematopoietic Stem Cell Transplantation. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
We assessed differences in presentation and response to therapy in 394 consecutive patients who developed acute or chronic graft-versus-host disease (GVHD) after receiving their first allogeneic transplantation (HSCT) from a 10/10 HLA allele-matched unrelated donor (MUD; n = 179) using calcineurin inhibitors or a T cell-replete haploidentical donor (haplo; n = 215) and post-transplantation cyclophosphamide at our center between 2005 and 2017. The median duration of follow-up for survivors was 52.5 months. The cumulative incidences for grade II-IV and grade III-IV acute GVHD at day 180 post HCT were similar, at 39% and 14%, respectively, for haplo-HSCT compared with 50% and 16% for MUD HSCT (P not significant). Haplo-HSCT recipients had a lower cumulative incidence of moderate to severe chronic GVHD, at 22% (severe, 19%), compared with 31% (severe, 29%) for MUD HSCT recipients (P = .026). The time to onset of moderate to severe chronic GVHD was faster for haplo-HSCT recipients (213 days versus 280 days; P = .011). Among patients with grade II-IV acute GVHD, there was no significant between-group difference in organ involvement, with skin the most affected (75% for haplo-HSCT versus 70% for MUD HSCT), followed by the gastrointestinal tract (71% versus 69%) and liver (14% versus 17% MUD). For chronic GVHD, haplo-HSCT recipients had less involvement of the eyes (46% versus 75% for MUD; P < .001) and of the joints/fascia (12% versus 36%; P = .001). Also for cGVHD patients, haplo-HSCT recipients and MUD HSCT recipients had similar all-cause mortality (22% versus 18%; P = .89), but the former were more likely to be off immunosuppression at 2 years post-HCT (63% versus 43%; P = .03) compared with MUD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Blood and Marrow Transplant Program at Northside Hospital, Atlanta, Georgia. Electronic address: msolh@bmtga.com.
- Blood and Marrow Transplant Program at Northside Hospital, Atlanta, Georgia.
- Center for Clinical and Translational Sciences, University of Texas Health Science Center at Houston, Houston, Texas.
Zitieren
APA
Solh, M. M., Baron, J., Zhang, X., Bashey, A., Morris, L. E., Holland, H. K., & Solomon, S. R. (2020). Differences in Graft-versus-Host Disease Characteristics between Haploidentical Transplantation Using Post-Transplantation Cyclophosphamide and Matched Unrelated Donor Transplantation Using Calcineurin Inhibitors. Biology of Blood and Marrow Transplantation, 26(11), 2082-2088. https://doi.org/10.1016/j.bbmt.2020.07.035
Vancouver
Solh MM, Baron J, Zhang X, Bashey A, Morris LE, Holland HK, et al. Differences in Graft-versus-Host Disease Characteristics between Haploidentical Transplantation Using Post-Transplantation Cyclophosphamide and Matched Unrelated Donor Transplantation Using Calcineurin Inhibitors. Biology of Blood and Marrow Transplantation. 2020;26(11):2082-2088. doi:10.1016/j.bbmt.2020.07.035
BibTeX
@article{Solh2020,
author = {Solh, Melhem M and Baron, Jimena and Zhang, Xu and Bashey, Asad and Morris, Lawrence E and Holland, H Kent and Solomon, Scott R},
title = {Differences in Graft-versus-Host Disease Characteristics between Haploidentical Transplantation Using Post-Transplantation Cyclophosphamide and Matched Unrelated Donor Transplantation Using Calcineurin Inhibitors},
journal = {Biology of Blood and Marrow Transplantation},
year = {2020},
volume = {26},
number = {11},
pages = {2082--2088},
doi = {10.1016/j.bbmt.2020.07.035}
}
EUVIMED